Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare C...(hnology company dedicated to speeding th...),Health

Date:10/28/2008

hnology company dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it may have the greatest impact. Raptor is involved in clinical development of its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease and Batten Disease, and its ConviviaTM product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical programs Raptor bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins which are designed to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTideTM, WntTideTM and NeuroTransTM.

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to develop any of its preclinical and clinical drug product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress
'/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Glendale Raptors Join Four Points by Sheraton Denver Southeast and Animal Planets Dr. Kevin Fitzgerald for Second Annual Halloween Costume Drive & Halloween Party for Kunsberg School at National Jewish Medical and Research Center
2. The Glendale Raptors Set Dates for Youth Rugby League and USA Rugby Youth Academy
3. Smith & Nephew Endoscopys BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
9. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
10. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
11. Anadys Pharmaceuticals to Present at Bio Investor Forum